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Homeostatic immune regulatory mechanisms can mediate premature termination of therapy-induced antitumor
T-effector cell responses. Administration of cyclophosphamide (CY) prior to intratumoral IL-12 and GM-CSF delivery
blocked post-treatment T-suppressor cell rebound via elimination of the pre-existing T-suppressor cell pool, allowed




Majority of immune-based cancer ther-
apies are designed to induce long-term
tumor-specific T-cell responses. In theory,
the initial effector T-cell response is
expected to eliminate established disease
with the subsequent memory phase con-
trolling recurrence. In practice however,
induction of antitumor cytotoxic T-cell
activity has not readily translated to effec-
tive tumor kill and relapse-free survival,
particularly in the clinical setting.
1 Studies
in the past decade have revealed that the
disconnect between the ability to promote
antitumor immunity and effective disease
eradication is associated with numerous
immunological roadblocks including
impaired trafficking and infiltration of
lymphocytes into tumors, rapid inactiva-
tion of infiltrating effector cells by the
tumor and the upregulation of T-cell
intrinsic negative regulatory checkpoint
molecules.
2 Whereas these findings under-
line the challenges associated with achiev-
ing and maintaining effective T-cell activity
in the tumor microenvironment, others
have demonstrated that such hurdles can
be overcome by extraneous immune mani-
pulation.
3 Thus, combination approaches
involving immune activation with concur-
rent blocking of tumor-mediated immune
suppressive and/or regulatory mechanisms
are now being tested in patients.
3
Studies in our laboratory demonstrated
that local and sustained delivery of IL-12
and GM-CSF to tumors can effectively
reverse immune suppression in the
tumor microenvironment leading to the
induction of both local and systemic
antitumor T-cell immunity and tumor
eradication.
4 Longer-term monitoring of
mice however, revealed that the effector
T-cell activity was limited to a 5 to 7 d
window and was rapidly countered by
suppressor T-cell resurgence.
5 Further
analysis demonstrated that an IFNc-
dependent switch in Dendritic cell
(DC) function in the TDLN was respons-
ible for the post-therapy regulatory cell
expansion.
6 More specifically, the IL-12-
IFNc axis was shown to promote the
expression of the tolerogenic enzyme
indoleamine 2,3 dioxygenase (IDO) in
post-treatment DC and skew their
function toward T-suppressor cell expan-
sion.
6 Importantly, repeated treatment
of persistent tumors resulted in the
exacerbation of the regulatory rebound,
which ultimately led to complete loss
of cytotoxic T-cell activity.
5 These find-
ings identified post-treatment homeo-
static immune regulation as a critical
impediment to successful tumor immune
therapy (Fig.1A). This observation is
not unique to our model as a similar
expansion of tumor-specific T-suppressor
cells following repeated tumor vaccina-





When administered prior to immune
therapy select chemotherapeutics such as
CY potentiate antitumor immunity via
multiple mechanisms including preferen-
tial depletion of T-suppressor cells, crea-
tion of a lymphopenia-associated cytokine
sink favorable to expansion of treatment-
induced effector cells and direct augmen-
tation of tumor immunogenicity.
8 To this
end we recently tested the ability of CY to
temper post-therapy regulatory surge via
preferential depletion of the pre-existing
T-suppressor cell pool in the tumor-
draining lymph nodes (TDLN). This
approach successfully diminished the
intensity of the regulatory surge and
extended the antitumor T-effector cell
activity window.
9 More importantly, when
administered repeatedly, chemoimmuno-
therapy promoted the complete cure of
established spontaneous mammary tumors
in 45% of her-2/neu transgenic FVBneuN
mice.
9 Further analysis revealed that
tumor cure was associated with the ability
to repeatedly block counter-regulation
thus allowing for long-term maintenance
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of antitumor cytotoxic T-cell activity
9
(Figure1A).
In separate studies we examined
whether targeting a different checkpoint
in the feedback inhibitory loop, i.e., block-
ing of the tolerogenic switch in post-
treatment TDLN DC, could be similarly
effective. To this end, administration of an
inhibitor of IDO, 1-methyl-d-tryptophan
(D-1MT) concurrent with IL-12 and
GM-CSF, suppressed the tolerogenic
switch and the subsequent suppressor
T-cell expansion resulting in enhanced
tumor eradication.
10 More recently,
we tested whether combining chemo-
immunotherapy with D-1MT, thereby
targeting both the source (pre-existing
T-suppressors) and the prime facilitator
(DC) of the regulatory surge, could further
enhance efficacy. The data shown in
Figure1B demonstrate that this strategy
achieved either long-term tumor arrest or
complete cure in 89% of the mice further
underlining the critical role of homeostatic
regulation in short-circuiting antitumor
T-effector cell activity.
Clinical Potential,
Pitfalls and Future Studies
Whereas the above data were obtained
in our specific pre-clinical model, we
expect this strategy to be applicable to all
treatments that are designed to promote
TH1 responses. A further advantage is the
fact that both CY and D-1MT have been
or are currently being evaluated in cancer
patients, which should facilitate the clini-
cal development of this concept. Finally,
the proposed approach could be parti-
cularly useful in the long-term manage-
ment of persistent and/or inoperable
tumors which are resistant to traditional
therapy.
Although the ability to block counter-
regulation allows for repeated activation of
antitumor cytotoxic T-cells, whether such
activity can be maintained indefinitely is
an important question. For example,
monitoring of CD8
+ T-cell cytotoxicity
during chronic treatment with CY +
IL-12/GM-CSF revealed that the intensity
of the cytotoxic response gradually
declined.
9 It is well-known that repeated
exposure to antigen can result in the
exhaustion of a clonal T-cell response.
In addition, preferential depletion of
T-suppressors by CY is not absolute and
some loss of tumor-specific CD8
+ T-cells
also occurs every time CY is administered.
Finally, inhibition of counter-regulation
is transient and regulatory cells eventu-
ally return. Whether any one (or a com-
bination) of the above mechanisms are
responsible for the inability to fully
restore cytotoxic activity after each cycle
of treatment is not yet known. Addi-
tional studies that are designed to define
the ultimate limits of chronic chemo-
immunotherapy and the mechanisms that
underlie such limitations are currently
underway.
Figure1. Chronic chemoimmunotherapy as long-term maintenance therapy. (A) CY-mediated
modulation of homeostatic immune regulation. Repeated immune stimulation results in
progressive intensification of the regulatory rebound and the inability to restore T-effector cell
activity. Preferential depletion of the pre-existing T-suppressor cell pool with CY tempers the
regulatory rebound allowing for repeated rescue of cytotoxic T-cell activity. Black horizontal bars
are representative of the intensity of the antitumor response. (B) Chronic chemoimmunotherapy
achieves complete cure of advanced spontaneous mammary tumors. FVBneuN mice bearing
established (100–200 mm
3) mammary tumors were treated with a single ip injection of CY followed
by a single intratumoral injection of IL-12 and GM-CSF microspheres as described
9 except that
D-1MT was added to the treatment regimen (2 mg/ml in 0.1 ml saline injected intratumorally
twice a week for the duration of the study). Microspheres were administered every 3 weeks for
a total of 3 cycles (arrows). Each line represents an individual mouse (n = 9).
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